Patient-centered Research: How Do Women Tolerate Nipple Fluid Aspiration As a Potential Screening Tool for Breast Cancer?

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jun 27

PMID 35761221

Authors

Susana I S Patuleia

Cathy B Moelans

Jasmijn Koopman

Julia E C van Steenhoven

Thijs van Dalen

Carmen C van der Pol

Agnes Jager

Margreet G E M Ausems

Paul J van Diest

Elsken van der Wall

Karijn P M Suijkerbuijk

Affiliations

Soon will be listed here.

Abstract

Background: Nipple fluid aspiration (NFA) is a technique to acquire nipple aspirate fluid (NAF), which is considered a rich source of breast-specific biomarkers. Originating directly from the mammary ducts, this liquid biopsy can offer insight into the process of carcinogenesis at its earliest stage and therefore could be of added value to the current imaging-based breast cancer screening tools. With that in mind, it is necessary to know how well NFA is tolerated.

Aim: To evaluate the participants' tolerability of NFA compared to breast imaging screening methods and blood draws.

Materials And Methods: Three cohorts of women underwent NFA: healthy women (n = 190), women diagnosed with breast cancer (n = 137) and women at high risk of developing breast cancer (n = 48). A 0-10 discomfort score of NFA, mammography, breast MRI and blood draws, was filled in at the study visits, which took place once or annually.

Results: The median discomfort rate of NFA was 1, which was significantly lower than the median discomfort of mammography and breast MRI (5 and 3, respectively, p < 0.001), but significantly higher than median discomfort for blood draws (0, p < 0.001). The great majority of women would undergo the procedure again (98%) and recommend it to others (97%).

Conclusion: This study shows that NFA was well tolerated by healthy women, women diagnosed with breast cancer and high-risk women. This makes NFA a feasible method to pursue as a potential future breast cancer early detection tool, based on resident biomarkers.

Trial Registration: NL41845.041.12 , NL57343.041.16 and NL11690.041.06 in trialregister.nl.

References

Geuzinge H, Heijnsdijk E, Obdeijn I, de Koning H, Tilanus-Linthorst M . Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk. Breast. 2021; 56:1-6. PMC: 7847961. DOI: 10.1016/j.breast.2021.01.002. View

Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst M . Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ. 2015; 351:h4901. PMC: 4595560. DOI: 10.1136/bmj.h4901. View

Mendat C, Mislan D, Hession-Kunz L . Patient comfort from the technologist perspective: factors to consider in mammographic imaging. Int J Womens Health. 2017; 9:359-364. PMC: 5441667. DOI: 10.2147/IJWH.S129817. View

van Asperen C, Jonker M, Jacobi C, Van Diemen-Homan J, Bakker E, Breuning M . Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomarkers Prev. 2004; 13(1):87-93. DOI: 10.1158/1055-9965.epi-03-0090. View

Hutton J, Walker L, Gilbert F, Evans D, Eeles R, Kwan-Lim G . Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study. Br J Cancer. 2011; 104(4):578-86. PMC: 3049597. DOI: 10.1038/bjc.2011.1. View

Sopik V, Nofech-Mozes S, Sun P, Narod S . The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat. 2015; 155(1):175-85. DOI: 10.1007/s10549-015-3666-y. View

SARTORIUS O . The biochemistry of breast cyst fluids and duct secretions. Breast Cancer Res Treat. 1995; 35(3):255-66. DOI: 10.1007/BF00665977. View

Jiwa N, Takats Z, Leff D, Sutton C . Breast health screening: a UK-wide questionnaire. BMJ Nutr Prev Health. 2021; 4(1):206-212. PMC: 8258049. DOI: 10.1136/bmjnph-2021-000266. View

Zubor P, Kubatka P, Kajo K, Dankova Z, Polacek H, Bielik T . Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management. Int J Mol Sci. 2019; 20(12). PMC: 6627787. DOI: 10.3390/ijms20122878. View

10.

Patuleia S, Hagenaars S, Moelans C, Ausems M, van Gils C, Tollenaar R . Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2020; 30(3):441-449. DOI: 10.1158/1055-9965.EPI-20-0770. View

11.

Van Goethem M, Mortelmans D, Bruyninckx E, Verslegers I, Biltjes I, Van Hove E . Influence of the radiographer on the pain felt during mammography. Eur Radiol. 2003; 13(10):2384-9. DOI: 10.1007/s00330-002-1686-6. View

12.

de Lange S, Bakker M, Monninkhof E, Peeters P, de Koekkoek-Doll P, Mann R . Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts. Clin Radiol. 2018; 73(8):759.e1-759.e9. DOI: 10.1016/j.crad.2018.04.002. View

13.

de Groot J, Branderhorst W, Grimbergen C, den Heeten G, Broeders M . Towards personalized compression in mammography: a comparison study between pressure- and force-standardization. Eur J Radiol. 2015; 84(3):384-391. DOI: 10.1016/j.ejrad.2014.12.005. View

14.

Suijkerbuijk K, van der Wall E, Meijrink H, Pan X, Borel Rinkes I, Ausems M . Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Fam Cancer. 2010; 9(3):321-5. PMC: 2921501. DOI: 10.1007/s10689-010-9344-7. View

15.

Schunemann H, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi P . Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann Intern Med. 2019; 172(1):46-56. DOI: 10.7326/M19-2125. View

16.

Rosenkranz G . A note on the Hodges-Lehmann estimator. Pharm Stat. 2009; 9(2):162-7. DOI: 10.1002/pst.387. View

17.

Jeukens C, van Dijk T, Berben C, Wildberger J, Lobbes M . Evaluation of pressure-controlled mammography compression paddles with respect to force-controlled compression paddles in clinical practice. Eur Radiol. 2019; 29(5):2545-2552. PMC: 6443616. DOI: 10.1007/s00330-018-5953-6. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Berg W, Blume J, Adams A, Jong R, Barr R, Lehrer D . Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology. 2009; 254(1):79-87. PMC: 2811274. DOI: 10.1148/radiol.2541090953. View

20.

PAPANICOLAOU G, HOLMQUIST D, BADER G, Falk E . Exioliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer. 1958; 11(2):377-409. DOI: 10.1002/1097-0142(195803/04)11:2<377::aid-cncr2820110223>3.0.co;2-a. View